You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
51 search results for: symposium
expert video
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
This video from the March 2024 ADVENT AD symposium features the final panel discussion and conclusion. Dr. Eric Simpson, Dr. Katrina Abuabara and Dr. Lawrence Eichenfield discuss topics related to early intervention in AD and the impact of the cumulative disease burden that may manifest as atopic or non-atopic, systemic comorbidities. The faculty also field several questions submitted by the audience. Dr. Simpson concludes the panel discussion with a brief overview of the symposium.
Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.
Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Katrina Abuabara discusses the concept of inflamm-aging in older adult patients. She explains how the term is defined through measures of systemic inflammatory markers and how immunosenescence can contribute to systemic comorbidities in older adults with AD.
Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.